MedCity News November 2, 2025
Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial endpoint data. Analysts see Clario’s offerings as highly complementary to PPD, the contract research organization that Thermo Fisher acquired in 2021.
Thermo Fisher Scientific, already a big player in providing services to the biopharmaceutical industry, is adding to its technology capabilities with the $9 billion acquisition of clinical trial software company Clario.
Clinical trials generate vast amounts of data that must be analyzed before a pharmaceutical or biotech company decides how to proceed. These outcomes or events are called clinical trial endpoint data. Clario’s technology integrates these data from devices, clinical trial sites, and patients during drug development and after a product reaches the...
Today's Sponsors
Today's Sponsor